PD Dr. Hans Jürgen Rech

Einrichtungen, die zum Universitätsklinikum Erlangen gehören Medizinische Fakultät Department of Medicine 3 – Rheumatology and Immunology

RESOLUTION OF VASCULAR INFLAMMATION IN PATIENTS WITH GIANT CELL ARTERITIS RECEIVING GLUCOCORTICOIDS, METHOTREXATE OR TOCILIZUMAB TREATMENT-DATA FROM THE ITALIAN/GERMAN RIGA STUDY (2019) Schonau V, Roth J, Tascilar K, Rech J, Schmidt D, Kuwert T, Crescentini F, et al. Conference contribution POLYAUTOIMMUNITY AND MAJOR ORGAN INVOLVEMENT PREVALENCE IN SJOGREN'S SYNDROME: THYROID, LIVER, LUNG AND KIDNEY AS TARGETS. A SINGLE CENTER CROSS SECTIONAL STUDY (2019) Valor L, Schenker H, Hagen M, Knitza J, Rech J, Schett G Conference contribution Analyses of association of psoriatic arthritis and psoriasis vulgaris with functional NCF1 variants (2019) Löhr S, Ekici AB, Uebe S, Büttner C, Köhm M, Behrens F, Böhm B, et al. Journal article Actual Treatment Options for Giant Cell Arteritis (2019) Moosig F, Schmalzing M, Aries PM, Henes J, Lamprecht P, Rech J, Witte T Journal article Interleukin 17 Blockade in Psoriasis Patients with Subclinical Joint Inflammation- Prospective Open Study to Influence the Course of the Disease by means of Secukinumab (2019) Kampylafka E, Oliveira I, Linz C, Lerchen V, Englbrecht M, Simon D, Rech J, et al. Conference contribution Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial Spondyloarthritis (2019) Riechers E, Baerlecken N, Baraliakos X, Achilles-Mehr Bakhsh K, Aries P, Bannert B, Becker K, et al. Journal article EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN THE GIACTA TRIAL (2019) Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, et al. Conference contribution Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial (2019) Tahir H, Mease PJ, Kavanaugh A, Reimold A, Rech J, Hall S, Geusens P, et al. Conference contribution EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL (2019) Stone J, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, et al. Conference contribution INHIBITION OF ARGINASE-1 EXPRESSION BY THE TRANSCRIPTION FACTOR FRA-1 IN MACROPHAGES EXACERBATES RHEUMATOID ARTHRITIS INFLAMMATION (2019) Hannemann N, Cao S, Schnelzer A, Jordan J, Eberhardt M, Schleicher U, Uebe S, et al. Conference contribution